<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820933</url>
  </required_header>
  <id_info>
    <org_study_id>MISP# 60720</org_study_id>
    <nct_id>NCT04820933</nct_id>
  </id_info>
  <brief_title>Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV</brief_title>
  <official_title>A Switch Clinical Trial of Antiretrovirals to Compare the Impact of Doravirine Versus Integrase Inhibitors With Backbone of Emtricitabine and Tenofovir Alafenamide on Instigators of Atherosclerosis in Persons With Chronic Treated HIV.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research application will explore the impact of the Non-nucleoside reverse transcriptase&#xD;
      inhibitor (NNRTI) doravirine in the setting of established Nucleoside reverse transcriptase&#xD;
      inhibitors (NRTIs) backbone [Tenofovir alafenamide (TAF) / Emtricitabine (FTC) as a possible&#xD;
      therapeutic strategy to minimize the detrimental impact of ART-related toxicities on&#xD;
      metabolism and instigators of atherosclerosis. Given the possible favorable role of NNRTI in&#xD;
      pathogenesis of HIV-related dyslipidemia and cardiovascular disease (CVD), this research will&#xD;
      provide mechanistic insights into HIV pathogenesis and safety data regarding doravirine&#xD;
      (DOR). These data may promote DOR as a robust &quot;HDL friendly&quot; and &quot;metabolism friendly&quot;,&#xD;
      therapeutic agent that may attenuate morbidity in chronic treated HIV infection. Towards this&#xD;
      aim, the investigators will study DOR-related effects on HDL (HDL-C levels and function) and&#xD;
      ex vivo assays that determine key molecular determinants of atherogenesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: To evaluate the relative in vivo impact of DOR on independent measures of HDL function&#xD;
      (antioxidant function, cholesterol efflux) compared to integrase inhibitors (raltegravir,&#xD;
      dolutegravir, elvitegravir, bictegravir) in the setting of TAF backbone in HIV infected&#xD;
      persons with dyslipidemia.&#xD;
&#xD;
      Aim 2: To evaluate the relative in vivo impact of DOR on ex vivo atherogenesis&#xD;
      (monocyte-derived foam cell efflux and chemotaxis) compared to integrase inhibitors&#xD;
      (raltegravir, dolutegravir, elvitegravir, bictegravir) in the setting of TAF backbone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2022</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDL function</measure>
    <time_frame>12 weeks post switch of antivirals</time_frame>
    <description>Primary outcome (instigator of atherosclerosis). This is a measure of the lipid peroxide content of HDL per specific amount of HDL relative to the measure of this value in a pooled healthy control (normalized ratio; no units).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocyte chemotaxis</measure>
    <time_frame>12 weeks post switch of antivirals</time_frame>
    <description>Primary outcome (instigator of atherosclerosis). This is a measure of the ability of isolated blood monocytes to migrate through a trans endothelial layer in an ex vivo model of atherogenesis. Units are % of monocytes that migrated (% chemotaxis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocyte derived foam cell formation of monocytes</measure>
    <time_frame>12 weeks post switch of antivirals</time_frame>
    <description>Primary outcome (instigator of atherosclerosis). This is a measure of the ability of isolated blood monocytes to take up lipids and form foam cells in an ex vivo model of atherogenesis. Units are % of monocytes that became foam cells (% Monocyte derived foam cell formation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>12 weeks post switch of antivirals</time_frame>
    <description>Secondary outcome (instigator of atherosclerosis). Units are mg/dl.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV I Infection</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Lipid Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Doravirine plus emtricitabine and tenofovir alafenamide fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PIFELTRO (doravirine) 100 mg tablet one daily for 3 months Descovy (200 mg emtricitabine + 10 mg tenofovir alafenamide fumarate) tablet one daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine 100 Mg</intervention_name>
    <description>Doravirine 100 Mg orally dail</description>
    <arm_group_label>Doravirine plus emtricitabine and tenofovir alafenamide fumarate</arm_group_label>
    <other_name>Descovy (200 mg emtricitabine + 10 mg tenofovir alafenamide fumarate)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Cases: Chronically infected and on anti-retroviral therapy with suppressed viremia for&#xD;
             at least 3 months (viral RNA &lt;50 copies per ml)&#xD;
&#xD;
          -  On stable antiretroviral therapy for &gt;6 months with Genvoya (elvitegravir 150&#xD;
             mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg; E/C/F/TAF) 2)&#xD;
             Biktarvy (bictegravir 50 mg/ emtricitabine 200 mg/tenofovir alafenamide 25 mg;&#xD;
             B/F/TAF).&#xD;
&#xD;
          -  Dyslipidemia (Defined based on use of lipid lowering medications or abnormal baseline&#xD;
             lipids (total cholesterol, triglycerides, high density lipoprotein): Rationale:&#xD;
             Enrolling participants with dyslipidemia will determine whether switching from&#xD;
             TAF/FTC/integrase inhibitor regimen to TAF/FTC/doravirine regimen will directly&#xD;
             improve the lipids over 3 months within the same participant.&#xD;
&#xD;
          -  Adequate renal function determined by the Cockcroft-Gault formula for creatinine&#xD;
             clearance (&gt;60 mL/min/1.73 m2&#xD;
&#xD;
          -  Able and willing to provide written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Pregnancy&#xD;
&#xD;
               -  Hepatitis; no evidence of acute hepatitis in the prior 30 days&#xD;
&#xD;
               -  History of severe renal impairment (eGFR &lt; 30 ml/min/1.73 m2)&#xD;
&#xD;
               -  History of severe or recent cardiac event&#xD;
&#xD;
               -  Current alcoholism or IV drug abuse&#xD;
&#xD;
               -  Use of systemic immunomodulatory medications (e.g. steroids) within 4 weeks of&#xD;
                  enrollment&#xD;
&#xD;
               -  Anemia precluding safe donation of blood (For men, anemia is typically defined as&#xD;
                  hemoglobin level of less than 13.5 gram/100 ml and in women as hemoglobin of less&#xD;
                  than 12.0 gram/100 ml).&#xD;
&#xD;
               -  Use of any investigational products within 4 weeks of enrollment&#xD;
&#xD;
               -  Any other clinical condition or prior therapy that, in the opinion of the&#xD;
                  investigator, would make the patient unsuitable for the study or unable to comply&#xD;
                  with the study requirements. Such conditions may include, but are not limited to,&#xD;
                  current or recent history of severe, progressive, or uncontrolled renal, hepatic,&#xD;
                  hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral&#xD;
                  disease.&#xD;
&#xD;
               -  Subjects who are on medications that are strong inducers of CYP3A (as these may&#xD;
                  decrease the efficacy of Stribild or Genvoya). Examples include phenobarbital,&#xD;
                  phenytoin, carbamazepine, and rifampin.&#xD;
&#xD;
               -  Subjects who are on medications that are cleared by CYP3A and that may be toxic&#xD;
                  with elevated drug levels (examples include Cisapride, ergotamine, Pimozide,&#xD;
                  Lurasidone, Lovastatin, and Simvastatin).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodoros Kelesidis, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theodoros Kelesidis, MD, PHD</last_name>
    <phone>3108257225</phone>
    <email>tkelesidis@mednet.ucla.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Theodoros Kelesidis, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>Cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

